Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Daniel F. Sahm, PhD
VP Global Microbiology Services & Chief Scientific Officer
IHMA
Poster(s):
(P-1355) Trends in Carbapenemase and Co-carbapenemase Production among Enterobacterales in Latin America: SMART 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1506)
In Vitro
Activity of Ceftazidime-Avibactam and Comparator Agents against
Pseudomonas aeruginosa
Collected from Patients with Presumed Hospital- and Community-acquired Respiratory Tract Infections as a Part of the ATLAS Global Surveillance Program 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1507)
In Vitro
Activity of Ceftazidime-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1508)
In Vitro
Activity of Aztreonam-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1509)
In Vitro
Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1510)
In Vitro
Activity of Ceftibuten-Avibactam and Comparator Agents Against Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2022 by Region
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1511)
In Vitro
Activity of Gepotidacin Against Molecularly Characterized
Neisseria gonorrhoeae
Isolates Exhibiting Reduced Susceptibility to Antibacterial Agents, 2018-2021
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1513)
In Vitro
Activity of Ceftaroline against Bacterial Pathogens from Pediatric Patients Collected During the ATLAS Global Surveillance Program in 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1514) Cefepime-taniborbactam Exhibits Limited Cross-resistance with Ceftazidime-avibactam and Ceftolozane-tazobactam against Carbapenem-nonsusceptible Enterobacterales and Multidrug-resistant
Pseudomonas aeruginosa
from the United States 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1518) Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam and Comparators Against Clinical MDR and DTR non-
Morganellaceae
Enterobacterales and
Pseudomonas aeruginosa
Stratified by Patient Age and Hospital Ward: SMART United States 2020-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1519) Susceptibility of Clinical Non-
Morganellaceae
Enterobacterales Isolates from Bloodstream and Respiratory Tract Infections to Imipenem/Relebactam and Comparators: SMART United States 2020-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1520) Addition of Relebactam Increases Susceptibility to Imipenem Among Imipenem-Intermediate
Pseudomonas aeruginosa
: Asia/Pacific SMART 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1521) Susceptibility of Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant
Pseudomonas aeruginosa
(CRPA) With and Without Carbapenemases to Cefepime-Taniborbactam and Comparators: GEARS Antimicrobial Surveillance Program, United States, 2018-2022
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT